NCT00688896 - Efficacy and Safety Study of JTT-705 in Combination With Pravastatin 40 mg in Patients With Type II Hyperlipidemia | Biotech Hunter

Enrollment

155

Participants

Timeline

Start Date

June 30, 2002

Primary Completion Date

April 30, 2003

Study Completion Date

March 31, 2004

Conditions

Type II Hyperlipidemia

Interventions

DRUG

JTT-705 600 mg and pravastatin 40 mg

"* JTT-705 300 mg tablets, 600 mg dose, 2 tablets, oral, once daily, immediately following breakfast and/or assessment~* Pravastatin 40 mg tablets, 40 mg dose, one tablet, oral, once daily, at bedtime"

DRUG

JTT-705 300 mg and pravastatin 40 mg

"* JTT-705 300 mg tablets, 300 mg dose, 1 tablet, oral, once daily, immediately following breakfast and/or assessment~* Placebo tablets, one tablet, oral, once daily, immediately following breakfast and/or assessments~* Pravastatin 40 mg tablets, 40 mg dose, one tablet, oral, once daily, at bedtime"

DRUG

Placebo and pravastatin 40 mg

"* Placebo tablets, 2 tablets, oral, once daily, immediately following breakfast and/or assessments~* Pravastatin 40 mg tablets, 40 mg dose, one tablet, oral, once daily, at bedtime"

Trial Locations (1)

Unknown

Amsterdam